A novel technique for the reduction of pesticide residues by a combination of low-intensity electrical current and ultrasound applications: A study on lettuce samples

In this study, effects of low-intensity electrical currents (200, 800 and 1400 mA), ultrasound frequencies (24 and 40 kHz) and their combinations were applied at the duration period of 2, 4, 6, 8, and 10 min for the degradation of captan, thiamethoxam and metalaxyl residues in lettuce samples. Residues of the pesticides were determined by gas chromatography with tandem mass spectrometry and electron capture detector. The results indicated that the combination of low-intensity electrical current and ultrasound was found to be effective for the reduction of the pesticides. The most effective combination was obtained to be current of 1400 mA and ultrasound frequency of 24 kHz at 10 min. Under this circumstance, 92.57, 81.99 and 93.09% of captan, thiamethoxam and metalaxyl residues were decreased, respectively. The findings suggest that the combination of low-intensity electrical current and ultrasound applications has an important potential for the degradation of pesticide residues

Dehydration kinetics of salmon and trout fillets using ultrasonic vacuum drying as a novel technique

WOS: 000358970900058PubMed: 26186871In this study, a novel ultrasonic vacuum (USV) drying technique was used to shorten the drying time of fish fillets. For this purpose, ultrasonic treatment and vacuum-drying were simultaneously performed to dehydrate salmon and trout fillets at 55 degrees C, 65 degrees C, and 75 degrees C. In addition, the USV technique was compared with vacuum-drying and oven-drying techniques. The dehydration kinetics of the fillets was successfully described by seven thin-layer drying models with R-2 range between 0.944 and 1.000. Depending on drying temperatures and fish species, the drying times could be shortened using the USV technique between 7.4% and 27.4% compared with vacuum-drying. The highest effective moisture diffusivity was determined in the fillets dried with the USV technique and they increased with increasing drying temperatures. Ultrasonic treatment accelerated the vacuum drying process for the fillets; therefore, this technique could be used to improve the efficiency of vacuum-drying for the fillets. (C) 2015 Elsevier B.V. All rights reserved

Asymptomatic giant prolapsing right atrial myxoma: Comparison of transthoracic and transesophageal echocardiography in pre-operative evaluation

We present a 65 years old asymptomatic patient with a giant prolapsing right atrial myxoma diagnosed echocardiographically and compare the transthoracic echocardiography and transesophageal two-dimensional features. Transesophageal echocardiography yielded a more accurate measurement of the correct dimensions of the tumour as compared with pathological findings, it also demonstrated clearly existing calcifications, the attachment and precise site of tumour pedunculation, showed haemodynamic changes, eliminated the possibility of other tumour foci. Transesophageal echocardiography gave correct anatomical and surgical data pre-operatively

Effect of ultrasound treatment on steady and dynamic shear properties of glucomannan based salep dispersions: Optimization of amplitude level, sonication time and temperature using response surface methodology

The present study investigated effect of different amplitude levels (40, 70 and 100%), sonication temperatures (40, 50 and 60 degrees C) and exposure times (3, 7 and 11 min) on steady shear properties: apparent viscosity (eta) shear stress (sigma), consistency coefficient (K), flow behavior index (n) and dynamic shear properties; storage modulus (G'), loss modulus (G ''), complex viscosity (eta*), complex modulus (G*) and loss tangent (tan delta) values of glucomannan based salep solution (SS) and salep drink (SD) samples. In addition, the steady and dynamic shear properties were optimized using ridge analysis in terms of amplitude level, sonication temperature and exposure times levels. Increasing amplitude level and sonication time decreased considerably the eta, sigma, K, G', G '' and eta* values of salep dispersions (SS and SD samples). However, sonication temperature did not have a remarkable effect on these properties. (C) 2011 Elsevier B.V. All rights reserved

Successful outcome of aspergillus brain abscess in a patient who underwent bone marrow transplantation for aplastic anemia

We report the course of an aspergillus brain abscess in an 18-year-old female patient who underwent bone marrow transplantation for aplastic anemia. The abscess was discovered on day 35 post-transplant, in a cranial computerized tomography (CT) scan performed for the evaluation of an unexplained headache. Meanwhile, she was receiving broad-spectrum antibacterials and liposomal amphotericin B for a right upper pulmonary lobe infiltrate. A percutaneous puncture of the cerebral lesion was performed; fungal elements were seen in the pus obtained and its culture yielded A. fumigatus. The dose of amphotericin B was increased, intraconazole was added and two more punctures were done. With these antifungals, the abscess regressed significantly; so, amphotericin B was discontinued after a cumulative dose of 6775 mg but itraconazole was maintained at 400 mg/day. At the last follow-up, seventeen months after detection of the abscess, the patient was well, without symptoms and the cerebral lesion diminished to a very small, thick-walled CT image

Frontline Nilotinib Treatment In Turkish Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results With 2 Years Of Follow-Up

Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1 <= 0.1% on the International Scale [BCR-ABL1(IS)]) by 12 months, was previously reported (66.1% [80% CI, 59.7%-72.0%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0% of patients achieved MMR, and 50.9% achieved MR4.5 (BCR-ABL1(IS) <= 0.0032%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.WoSScopu

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

WOS: 000384401200003PubMed ID: 27501474Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL10.1% on the International Scale [BCR-ABL1(IS)]) by 12months.Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300mg twice daily. This analysis was based on the first 12months of follow-up in a 24-month study.Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1(IS) 0.0032%) by 12months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP.Novartis Pharmaceuticals CorporationNovartisThis study was funded by Novartis Pharmaceuticals Corporation